rituximab [MabThera/Rituxan]
DrugAs prescribed by physician
NCT Number: NCT01075477
This observational study will assess the execution, efficacy and safety of treatment with MabThera in patients with rheumatoid arthritis. Data from patients receiving MabThera according to local treatment guidelines will be collected for 29 months. Target sample size is 100-200 patients.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Helsinki, Finland
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
As prescribed by physician
Time frame: 29 months
Time frame: 29 months
Time frame: 29 months
Hoffmann-La Roche
Industry
Naturalistic Prospective Non-interventional Study on Rheumatoid Arthritis (RA) Patients Treated With Rituximab According to Local Treatment Guidelines
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00055055
Arthritis, Arthritis, Rheumatoid
Bethesda, Maryland, United States
View Trial DetailsNCT05638854
Arthritis, Arthritis, Rheumatoid
Melbourne, Australia
View Trial DetailsNCT05718583
Arthritis, Arthritis, Rheumatoid
New York, United States
View Trial DetailsNCT01521923
Arthritis, Arthritis, Rheumatoid
Birmingham, Alabama, United States
View Trial Details